BTCC / BTCC Square / Global Cryptocurrency /

Eli Lilly’s $262M Acquisition of Adverum Strengthens Gene Therapy Portfolio

Eli Lilly’s $262M Acquisition of Adverum Strengthens Gene Therapy Portfolio

Author:

Global Cryptocurrency

Published:

2025-10-24 20:01:02

12

2

BTCCSquare news:

Eli Lilly (LLY) has announced a $261.7 million acquisition of Adverum Biotechnologies (ADVM), a clinical-stage biotech specializing in gene therapies for ocular diseases. The deal includes an upfront payment of $3.56 per share, with potential milestone payouts reaching $12.47 per share. Adverum’s stock surged 17% on the news, while Lilly shares ROSE 2%.

The centerpiece of the transaction is Ixo-vec, a Phase 3 gene therapy for wet age-related macular degeneration. The single-injection treatment could disrupt current standards of care requiring frequent ocular injections. Regulatory designations suggest accelerated approval pathways, aligning with Lilly’s strategic expansion in genetic medicines for underserved patient populations.

By:

Apro Token Price Crash: 5 Reasons Behind the 35% Drop

|Square

Get the BTCC app to start your crypto journey

Download on the App Store GEI IT ON Google Play

Get started today Scan to join our 100M+ users

Risk warning: Digital asset trading is an emerging industry with bright prospects, but it also comes with huge risks as it is a new market. The risk is especially high in leveraged trading since leverage magnifies profits and amplifies risks at the same time. Please make sure you have a thorough understanding of the industry, the leveraged trading models, and the rules of trading before opening a position. Additionally, we strongly recommend that you identify your risk tolerance and only accept the risks you are willing to take. All trading involves risks, so you must be cautious when entering the market.

The world’s longest-running cryptocurrency exchange since 2011 © 2011 - 2025 BTCC.com. All rights reserved

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.